CymaBay Therapeutics CEO and leadership

Mr. Shah has served as our President and Chief Executive Officer since March 2017. Previously, he served as our Chief Financial Officer since December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Mr. Shah received a M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.

Dr. McWherter has been Senior Vice President and Chief Scientific Officer since the inception of CymaBay in 2013. Previously he was Senior Vice President, Research and Preclinical Development at Metabolex (2007-2013). From 2003-2007, he served as Vice President and Cardiovascular Research Therapy Head for Pfizer Global Research and Development. He moved to Pfizer after its acquisition of Sugen where he had been in the role of Vice President of Drug Discovery from 2001 to 2003. Dr. McWherter formerly served as Adjunct Assistant Professor of Molecular Biology and Pharmacology at the Washington University School of Medicine in St. Louis and as Chairman of the Board of Directors of the Greater St. Louis Division of the American Heart Association. Dr. McWherter obtained his Ph.D. in chemistry from Cornell University.

Klara A. Dickinson is the Chief Regulatory and Compliance Officer at CymaBay Therapeutics. Ms. Dickinson previously spent 3 years with CoTherix, Inc. and most recently served as VP, Regulatory Affairs and Healthcare Compliance Officer for the company. In that role, Ms. Dickinson led the filing of the NDA and label negotiations for the company’s initial product, Ventavis® (iloprost) Inhalation Solution. Ms. Dickinson has also held various positions at Scios, Inc. and Dey Laboratories, a subsidiary of Mylan Inc. Ms. Dickinson holds a BS in biology from the College of Great Falls in Montana and is certified by the Regulatory Affairs Certification Board.

Mr. Shah has served as our President and Chief Executive Officer since March 2017. Previously, he served as our Chief Financial Officer since December of 2013. Prior to that he served as a consultant and acting Chief Financial Officer for us from June 2012 to December 2013. From 2010 to 2012, Mr. Shah served as Director, Health Care Investment Banking for Citigroup Inc., where he was responsible for managing client relationships and executing strategic and financing related transactions for clients focused in life sciences. From 2004 to 2010 Mr. Shah was employed with Credit-Suisse, last serving in the capacity as Vice President, Health Care Investment Banking Group. Mr. Shah currently serves on the Executive Advisory Board of the Chemistry of Life Processes Institute at Northwestern University. Mr. Shah received a M.B.A. from Carnegie Mellon University Tepper School of Business and M.S. and B.S. degrees in Biomedical Engineering from Northwestern University.